Blistering News: Delcath Systems, Inc. (NASDAQ CTH)
By Koko Saunders -
January 20, 2017

Delcath Systems, Inc. (NASDAQ CTH) traded with the volume of 5.51 Million in the previous trading session. The Stock opened its session at $0 and closed at $0.31 by showing decrease of -22.85 percent. Delcath Systems, Inc. has 1 year price target of $16. The company reported its last quarter on Sep 16.

On Sep 16 Delcath Systems, Inc. (NASDAQ CTH) reported its EPS in the last quarter as $-0.66/Share beating the analyst estimate of $-3.29/Share by the difference of $2.63. This showed the surprise of 79.9% in the last quarter earnings.

The 1 analysts offering 12-month price forecasts for Delcath Systems Inc have a median target of 16.00, with a high estimate of 16.00 and a low estimate of 16.00. The median estimate represents a +5,056.30% increase from the last price of 0.31. (CNN MONEY)

Many Analysts provided their foresight on Revenue Estimates of Delcath Systems, Inc. where they believe that the company has the potential to earn average revenue of $620 Million for the current quarter. According to their predictions High & Low revenue estimates are 620 Million and 620 Million respectively.

Delcath Systems, Inc. (NASDAQ CTH) topped its 52-week high price of $7.2 on Jan 22, 2016 and 52-Week Low Price of $0.3 on Jan 19, 2017. The Stock currently has the market capitalization of $770000, P/E (price to earnings ttm) of 0 and Weekly volatility of 33.19% and monthly volatility of 25.62% respectively.

Delcath Systems, Inc. Gross Margin percentage stands at 72.9% while its Operating Margin for trailing twelve month is 0 percent and Profit margin (ttm) is 0 Percent. The stock is currently moving above its 20-Day Simple Moving Average of -78.56% with the 50-Day Simple Moving Average of -78.56 percent. Currently, the company has SMA200 (200-day simple moving average) of -98.95 Percent. The Stock has YTD (year to date) performance of -66.27 percent.

Many research firms have provided their ratings on Delcath Systems, Inc. (NASDAQ CTH) where BioLogic Equity Research provided Sell rating on the stock on 8-Jun-10. Other firms include Roth Capital giving Buy rating on 22-Apr-10.

The latest Insider trade was made on 15 Jun 2016 where Purpura John Officer did a transaction type “Sell” in which 11738 shares were traded at a price of $0.25. Another insider trade includes Officer Keck (Barbra C) who also initiated a transaction in which 8561 shares were traded on 15 Jun 2016 as “Sell”.

Company Profile:

Delcath Systems, Inc. has developed a system, the Delcath system, to isolate the liver from the general circulatory system and to administer chemotherapy and other therapeutic agents directly to the liver.